Amilomotide

Drug Profile

Amilomotide

Alternative Names: Alzheimer's disease virus-like particle-based vaccine - Novartis; Alzheimer's disease VLP-based vaccine - Novartis; Beta-amyloid protein immunotherapy - Novartis; CAD 106; Immunodrug™ for Alzheimer's disease - Novartis

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Cytos Biotechnology
  • Developer Cytos Biotechnology; Novartis
  • Class Alzheimer vaccines; Antidementias; Neuroprotectants; Virus-like particle vaccines
  • Mechanism of Action Amyloid beta-protein inhibitors; Immunomodulators; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Alzheimer's disease
  • Discontinued Hypersensitivity; Rheumatoid arthritis

Most Recent Events

  • 15 Feb 2017 Discontinued - Phase-II for Alzheimer's disease in European Union, USA, Switzerland (SC)
  • 13 Jun 2016 Phase-II/III clinical trials in Alzheimer's disease in Belgium and Finland (IM) (EudraCT2015-002715-15)
  • 22 Dec 2015 Phase-II/III clinical trials in Alzheimer's disease in USA (IM) (NCT02565511)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top